Dr. Reddy's Secures Health Canada Approval for Generic Semaglutide Injection
Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, becoming the first company to get marketing authorization. This enables commercialization, sale, and distribution in Canada, a key market for Semaglutide. The approval highlights Dr. Reddy's expertise in complex generics and peptide-based therapeutics.
Gaining marketing authorization in a key global market like Canada for a significant drug like Semaglutide Injection is expected to have a substantial positive impact on the company's revenue and market position.
The approval of a new drug by a major regulatory authority like Health Canada is a significant positive development for the company, opening up a new market and revenue stream.
Dr. Reddy's Laboratories Limited announced on April 29, 2026, that it has received a Notice of Compliance (NOC) from Health Canada for its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. This approval makes Dr. Reddy's the first company to receive marketing authorization for generic Semaglutide Injection in Canada, ahead of Health Canada's review target date. The authorization covers the 2 mg/pen and 4 mg/pen (1.34 mg/mL) formulations, positioning Dr. Reddy's to supply this treatment option to Canadian patients.
The company highlighted the significant prevalence of diabetes in Canada, with approximately 3.9 million people diagnosed and over 6% living with prediabetes. Semaglutide, as a GLP-1 receptor agonist therapy, has demonstrated efficacy in improving glycemic control in adults with type 2 diabetes. Canada is recognized as the second-largest market globally for Semaglutide.
This approval underscores Dr. Reddy's expertise in complex generics and peptide-based therapeutics, supported by in-house API and formulation development capabilities. The API is produced internally, with the finished product manufactured by their partner, OneSource Specialty Pharma Limited. Erez Israeli, CEO of Dr. Reddy's, expressed that this milestone is significant for their GLP-1 journey and reinforces their commitment to expanding access to affordable and high-quality diabetes treatments in Canada. The company aims to ensure a reliable supply and further strengthens its presence in regulated markets.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.